Novonesis Expects Results From Weight-Loss Drug Supplement Study in 2027
The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based…
Novo Nordisk’s Wegovy: Pioneering Weight Loss Innovation
Novo Nordisk, the Danish pharmaceutical giant, is intensifying its pursuit of weight-loss innovation with a new late-stage study…
Novo Nordisk’s Strategic Move with Wegovy: A New Study in the Obesity Drug Race
Novo Nordisk, a leading Danish pharmaceutical company, has embarked on a late-stage study to identify the minimal effective…
Eli Lilly’s Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official — and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication…
Pfizer’s Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound
The past few years have been rough on Pfizer (NYSE: PFE). The company has generally posted subpar financial…
Why Is Everyone Talking About Novo Nordisk?
Novo Nordisk (NYSE: NVO) is well-known for its strong position in the GLP-1 market. The company’s brands in…
Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint
Researcher looking through microscope ©gebakax Novo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its…
Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb
Novo Nordisk shares tumbled Tuesday after the Danish pharmaceutical giant released updated financial guidance that, while improved from…
Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
Novo Nordisk A/S First GLP-1 pill approved in the European Union for the treatment of obesity and overweight…
Watch Out, Eli Lilly and Novo Nordisk: Amgen’s Monthly Weight Loss Drug Has 6 Phase 3 Trials Running — and It’s Coming for Your Patients
Amgen (NASDAQ: AMGN) is betting that the convenience of its weight loss treatment will make it a winner,…
Where Will Novo Nordisk Stock Be in 3 Years?
Novo Nordisk (NYSE: NVO) fell by 29% over the last 12 months, and that’s making investors antsy about…
Novo Nordisk looks to block Eli Lilly weight-loss drug ads
Lilly on Tuesday denied any wrongdoing, saying it stood by its advertising and would vigorously defend itself. The U.S. drugmaker…